University of Southern California
USC Norris Comprehensive Cancer Center

Not logged in...

If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 1B-11-1

Breast Cancer Blood Biorepository.

Type: Other
Phase: Not Applicable
Status: Open to Accrual
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Julie Lang, M.D.
Other Trial Staff:  Cristina De Leon, Coordinator, Grace Facio, Coordinator, Margarita Carranza, D.M., Kristy Sartor Massopust, Coordinator, America Casillas-Lopez, Coordinator, America Casillas-Lopez, Coordinator, Akshara Singareeka Raghavendra, Coordinator, Sodech Kim, Coordinator, Apoorva Vishwanath, D.M., Alix Cohen, Coordinator, Brigitte Torres, Coordinator

Staff may log in to see study documents.

You may participate in this study if:
1Individuals of all racial and ethnic groups who are 18 years or older
2Cohort 1: Women with a high-risk of breast cancer but no evidence of disease, including: (a) Women with BRCA1 or BRCA2 germline mutations; (b) Women with a family members with breast and/or ovarian cancer; (c) Women of Ashkenazi Jewish descent; (d) Women with a diagnosis of ovarian cancer; (e) Women with high mammographic breast density (BIRAD score 4-5); (f) Women with a history of atypical ductal hyperplasia Cohort 2: Women with stage I-III invasive ductal or lobular breast cancer, to be enrolled prior to definitive surgery for breast cancer Cohort 3: Women with stage IV invasive ductal or lobular breast cancer, to be enrolled at any time Cohort 4: Women with ductal or lobular carcinoma in situ, to be enrolled at the time of diagnosis and before definitive surgery Cohort 5: Normal controls, includes healthy family members of patients, patients with benign breast disorders, patients from families carrying a known genetic mutation who themselves are found not to carry the mutation.
3Signed an approved study-specific informed consent and HIPAA

You may not participate in this study if:
1Hgb <8.0
2Pregnancy (except for Cohort 5)

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.